PARP Inhibitors in Breast and Ovarian Cancer with BRCA Mutations: a Meta-analysis of Survival

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Mar 11

PMID 33705352

Citations 13

Authors

Fengping Shao

Yaoyun Duan

Yunhe Zhao

Yinguang Li

Jun Liu

Cai Zhang

Shanyang He

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the efficacy of poly ADP ribose polymerase (PARP) inhibitors (PARPis) in breast and ovarian cancer with (BReast CAncer susceptibility gene) mutation (BRCAm).

Methods: We conducted a meta-analysis of randomized controlled, phase II or III trials by searching of electronic databases from inception to September 1, 2020. The efficacy of PARPis measured by hazard ratios (HRs) and 95% confidence intervals (95% CIs) for progression free survival (PFS) and overall survival (OS) of patients.

Results: By addition of PARPis to conventional therapy, breast or ovarian cancer patients carrying BRCAm significantly benefited PFS (breast cancer: HR 0.64, 95% CI=0.55-0.75, P<0.001; ovarian cancer: HR 0.33, 95% CI=0.27-0.42, P<0.001), but OS of patients did not increase significantly in these two cancer types (breast cancer: HR 0.87, 95% CI=0.76-1.01, P=0.065; ovarian cancer: HR 0.78, 95% CI=0.61-1.01, P=0.058). For ovarian cancer patients carrying BRCAm, the use of therapy with PARPis yielded longer PFS at the stage of newly diagnosed than the stage of recurrence (22.5 months vs 9.6 months).

Conclusion: PARPis were beneficial to all with BRCAm, but they were "most" beneficial to the ovarian cancer subset when administered early after diagnosis, rather than after recurrence.

Citing Articles

Advances in DNA/RNA Sequencing and Their Applications in Acute Myeloid Leukemia (AML).

Ahmed F, Zhong J Int J Mol Sci. 2025; 26(1.

PMID: 39795930 PMC: 11720148. DOI: 10.3390/ijms26010071.

Efficacy and safety of PARP inhibitor maintenance therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials.

Sun G, Liu Y Front Pharmacol. 2024; 15:1460285.

PMID: 39376601 PMC: 11457084. DOI: 10.3389/fphar.2024.1460285.

Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance.

Berckmans Y, Ene H, Ben-Meir K, Martinez-Conde A, Wouters R, Van den Ende B Front Oncol. 2024; 14:1402851.

PMID: 38993641 PMC: 11238040. DOI: 10.3389/fonc.2024.1402851.

Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.

Murawski M, Jagodzinski A, Bielawska-Pohl A, Klimczak A Cells. 2024; 13(4.

PMID: 38391958 PMC: 10886918. DOI: 10.3390/cells13040345.

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Alameddine Z, Niazi M, Rajavel A, Behgal J, Keesari P, Araji G Curr Oncol. 2023; 30(10):9262-9275.

PMID: 37887569 PMC: 10605202. DOI: 10.3390/curroncol30100669.

References

Poggio F, Bruzzone M, Ceppi M, Conte B, Martel S, Maurer C . Single-agent PARP inhibitors for the treatment of patients with -mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. ESMO Open. 2018; 3(4):e000361. PMC: 6012556. DOI: 10.1136/esmoopen-2018-000361. View

Al Hadidi S, Aburahma A, Badami S, Upadhaya S . PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials. Oncol Res Treat. 2018; 41(4):226-235. DOI: 10.1159/000486418. View

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-92. DOI: 10.1056/NEJMoa1105535. View

Litton J, Hurvitz S, Mina L, Rugo H, Lee K, Goncalves A . Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020; 31(11):1526-1535. PMC: 10649377. DOI: 10.1016/j.annonc.2020.08.2098. View

Pujade-Lauraine E, Ledermann J, Selle F, Gebski V, Penson R, Oza A . Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9):1274-1284. DOI: 10.1016/S1470-2045(17)30469-2. View

Pilie P, Gay C, Byers L, OConnor M, Yap T . PARP Inhibitors: Extending Benefit Beyond -Mutant Cancers. Clin Cancer Res. 2019; 25(13):3759-3771. DOI: 10.1158/1078-0432.CCR-18-0968. View

Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C . Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials. Biosci Rep. 2020; 40(3). PMC: 7080644. DOI: 10.1042/BSR20192226. View

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

10.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

11.

Bang Y, Im S, Lee K, Cho J, Song E, Lee K . Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J Clin Oncol. 2015; 33(33):3858-65. DOI: 10.1200/JCO.2014.60.0320. View

12.

Han H, Dieras V, Robson M, Palacova M, Marcom P, Jager A . Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2017; 29(1):154-161. PMC: 5834075. DOI: 10.1093/annonc/mdx505. View

13.

Weston V, Oldreive C, Skowronska A, Oscier D, Pratt G, Dyer M . The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010; 116(22):4578-87. DOI: 10.1182/blood-2010-01-265769. View

14.

Oza A, Cibula D, Benzaquen A, Poole C, Mathijssen R, Sonke G . Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2014; 16(1):87-97. DOI: 10.1016/S1470-2045(14)71135-0. View

15.

Coleman R, Fleming G, Brady M, Swisher E, Steffensen K, Friedlander M . Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019; 381(25):2403-2415. PMC: 6941439. DOI: 10.1056/NEJMoa1909707. View

16.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

17.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016; 17(11):1579-1589. DOI: 10.1016/S1470-2045(16)30376-X. View

18.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

19.

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

20.

Konstantinopoulos P, Norquist B, Lacchetti C, Armstrong D, Grisham R, Goodfellow P . Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020; 38(11):1222-1245. PMC: 8842911. DOI: 10.1200/JCO.19.02960. View